Precigen (STU:I5X) Total Equity: €17.50 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:I5X Precigen Inc STU:I5X
63 GF Score
Price €4.52
GF Value €5.38
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Precigen Total Equity?

Precigen STU:I5X -0.44% 63 Total Equity is €17.50 Mil as of Mar. 2026. GuruFocus rates STU:I5X with a GF Score™ of 63/100 and a GF Value™ of €5.38 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Precigen's total equity for the quarter that ended in Mar. 2026 was €17.50 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Precigen Total Equity Historical Data

* Premium members only.

The historical data trend for Precigen's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Precigen Total Equity Chart

Precigen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 95.00 119.19 108.66 36.78 17.86

Precigen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.01 -31.89 35.67 17.86 17.50
STU:I5X
63GF Score
Precigen Inc STU:I5X
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Precigen Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Precigen's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=132.801-114.943
=17.86

Precigen's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=119.912-102.409
=17.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €17.50 Mil mean?
Precigen (STU:I5X) has a Total Equity of €17.50 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Precigen and its competitors.
Is Precigen's Total Equity too high?
Precigen's current Total Equity is €17.50 Mil. Overall, Precigen has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Precigen's Total Equity compare to KARD and SLBT?
Precigen's Total Equity of €17.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Precigen and its competitors. Precigen's current Total Equity is €17.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precigen stock overvalued right now?
Based on GuruFocus' analysis, Precigen (STU:I5X) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.38, compared to a current price of €4.52 — trading 16% below its estimated fair value. The current Total Equity is €17.50 Mil. Precigen's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Precigen (STU:I5X), the current Total Equity is €17.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Precigen (STU:I5X) Overvalued in 2026?

Based on GuruFocus' analysis, Precigen stock appears to be undervalued. The current stock price of €4.52 is trading 16% below its estimated GF Value™ of €5.38. GuruFocus considers Precigen to be Modestly Undervalued.

Key valuation signals for STU:I5X:

  • Total Equity: €17.50 Mil
  • GF Value™: €5.38 vs. price of €4.52 (16% below fair value)
  • GF Score™: 63/100 with 8 warning signs

No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precigen Business Description

Other Exchanges PGEN:USA
Address 20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
63GF Score

Get the complete analysis for STU:I5X

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.52
Price
€5.38
GF Value